Further evidence for this mechanism is presented by the observation that hexadecylphosphocholine, an inhibitor of PC synthesis shows synergistic antiproliferative effects with Ara-C. We conclude that the rapid cell lysis described during high-dose Ara-C treatment seems to be mediated by reduction of cell membrane PC content.
Introduction
Cytosine arabinoside (Ara-C) has been used as a therapeutic agent in the treatment of leukemia for many years. Although its major mechanism of action has been agreed upon to be the inhibition of DNA polymerase 1, 2 and DNA chain termination by incorporation of Ara-CTP into newly synthesized DNA at S phase, 3, 4 for several reasons other mechanisms of action for Ara-C have been discussed recently. First, in clinical trials high-dose Ara-C therapy has proved to be still effective in relapsed leukemia and leukemia refractory to lower doses of Ara-C, suggesting the existence of alternative mechanisms of action at high Ara-C concentrations. [5] [6] [7] Second, leukemic blast clearance during high-dose treatment 8 and cell lysis in leukemic cell cultures at more than 50 M Ara-C 9 is very rapid, pointing to a mechanism that seems to be rather independent of DNA-associated processes, since on average, maximally 23% of leukemic cells are usually in S phase with an approximate duration of this phase of over 48 h. 10, 11 In search of alternative modes of action it was found, for instance, that Ara-C may be involved in cellular signal transduction by induction of PKC and c-jun expression in HL 60 and other cell lines [12] [13] [14] [15] as well as a moderation in the downregulation of c-myc, 16 events that may influence cell growth and differentiation. Further observations include Ara-C-induced DNA fragmentation in U937 cells similar to DNA fragmentation under apoptosis. 17 However, these mechanisms generally act on cell proliferation and integrity with significantly slower kinetics. Rapid cell lysis most probably has to involve substantial and direct damage of cell membranes.
A possible target structure for Ara-C involvement in cellular membranes may be the metabolism of the major membrane phospholipid phosphatidylcholine (PC), which is synthesized from phosphocholine and CTP via CDP choline, catalyzed by the enzyme CTP phosphocholine cytidylyltransferase (E.C. 2.7.7.15). Ara-C could interfere with this synthesis through its metabolites. Indeed, the counterpart of CDP-choline, Ara-CDP-choline, has been identified in cultured leukemic cells and leukemic blasts. 18, 19 Kucera and Capizzi 20 have investigated the effects of several Ara-C metabolites on the three main enzymes of PC synthesis in vitro and found that Ara-CTP actually inhibits CTP phosphocholine cytidylyltransferase and that the high level of Ara-CDP choline measured in cells treated with high doses of Ara-C were most probably generated by a reversal of the function of the enzyme CDP choline: 1,2-diacylglycerol cholinephosphotransferase (E.C. 2.7.8.2.) using Ara-CMP and PC as substrates. Reversal of this reaction is not unusual and has been shown to occur in several tissues with phosphatidylcholine and CMP forming CDP choline and diacylglycerol. 21, 22 These studies discuss the hypothesis that Ara-C could probably lead to cell lysis by impairment of membrane lipid homeostasis.
The aim of our study was to gain more insight into the potential role of Ara-C in phospholipid metabolism and to investigate the significance of PC synthesis for Ara-Cmediated toxicity.
Materials and methods
Ara-C was from Upjohn (Heppenheim, Germany), 3 H-Ara-C (20 Ci/mmol) and L-lyso-3-phosphatidylcholine, 1-1-14 C palmitoyl (56 mCi/mmol) was from Amersham (Braunschweig, Germany). Lipid standards, lysophosphatidylcholine, cytidine metabolites, the cholesterol determination kit, the protein determination kit and Trypan blue were from Sigma (Munich, Germany) and solvents from JT Baker (Deventer, The Netherlands) or Merck (Darmstadt, Germany). Tetrabutylammonium phosphate (PIC A low UV) was from Waters (Ekrath, Germany). The phosphorus determination kit was from Serva (Munich, Germany). Hexadecylphosphocholine (HePC) was provided by Asta Pharma (Frankfurt, Germany). Thin-layer chromatography plates were from Merck. Cell culture medium and fetal calf serum (FCS) were from Gibco/Life Technologies (Eggenstein, Germany) or from Bio-Whittaker (Verviers, Belgium). All other chemicals were of commercial grade and used without further purification.
For most experiments the human promyelocytic leukemia cell line HL 60 and the Burkitt lymphoma line Raji were used. Further cell lines tested were the monocytic leukemia cell line U 937 and the T cell lines Jurkat, TIB and HUT 78. All cells are of human origin and were obtained from the American Type Culture Collection (ATCC, Rockville, MD, USA). Primary AML blasts were collected from bone marrow aspirates of patients by separation of total cells by Ficoll gradient centrifugation. The cells were maintained in Click's/RPMI 1640 medium supplemented with 20 mM N-2-hydroxyethyl-piperazine-NЈ-3-ethanesulfonic acid (HEPES), pH 7.3, 100 U/ml penicillin, 100 g/ml streptomycin, 10 mM L-glutamin and 10% FCS. Cell cultures were incubated at 37°C, 5% CO 2 and 95% humidity. Cultures were checked for mycoplasma contamination at regular time intervals using the hybridization kit from Biermann (Bad Nauheim, Germany). For experiments the cells were washed twice in fresh medium, counted and seeded to the desired density in fresh culture flasks.
Viability test
Cells (2 × 10 5 /ml) were incubated in six-well plates (3 ml medium/well) with increasing concentrations of Ara-C for 48 h at the above mentioned conditions. After the incubation period, cell number and viability were determined in a Neubauer cell counting chamber using the Trypan blue dye exclusion test. 23 Half-maximal growth inhibition (IC 50 ) and half-maximal toxicity (LC 50 ) were determined by intrapolation of the values obtained by dose-response assay curves.
Lipid composition
Cellular lipids were extracted from a known number of cells with chloroform/methanol/water (8/10/4, by volume) by the method of Bligh and Dyer. 24 The lipid extract was dried under nitrogen at 60°C. The lipid film was redissolved in chloroform/methanol (1/1 by volume) and applied to highperformance thin-layer chromatography (HPTLC) plates (Merck) using a Camag Linomat IV sample applicator (Camag, Berlin, Germany). The plates were developed in chloroform/methanol/acetic acid/water (60/50/5/2, by volume) for the analysis of phospholipids or in hexane/isopropanol (5/7 by volume) for the analysis of neutral lipids. After drying, the plates were immersed in an aqueous copper sulfate (10%) solution, made acidic with 8% phosphoric acid. The plates were charred and the charred spots were quantified using a Personal Densitometer (Molecular Dynamics, Krefeld, Germany) as described by Rustenbeck and Lenzen 25 and by Kö tting et al. 26 Ara-C-induced changes in lipid composition HL 60 and Raji cells (1 × 10 6 cells/ml; 12 ml) were initially incubated with Ara-C concentrations ranging from 0.1 to 100 M. At the beginning of the incubation period an aliquot was taken for cell counting and two aliquots of 1 ml were taken as control. After 4 h, another aliquot was taken for cell counting and the cells were washed with Ara-C-free medium. Two samples of 1 × 10 6 cells were separated for lipid extraction after the cells were counted. At 8, 12 and 24 h the cells were counted again and two other aliquots were taken for lipid extraction and lipid composition analysis. Since the maximum changes in lipid composition occurred at an Ara-C concentration of 50 M and no additional changes were observed up to 100 M, in all further experiments an Ara-C concentration of 50 M was employed.
Lysophosphatidylcholine protection experiments
Cell suspensions (2 × 10 5 cells/ml, 10 ml) were incubated with 0 or 10 g/ml lysophosphatidylcholine and 0 or 50 M Ara-C, respectively. HL 60 cells were also treated with doxorubicin instead of Ara-C. After 4 h of incubation, the cell suspensions were washed and aliquots were used for cell counting. The remainder of the suspensions was incubated for another 20 h in the presence or absence of lysophosphatidylcholine but without Ara-C, and again aliquots were taken for cell counting. To some of the cultures treated with lysoPC a second addition of lysoPC was made and the cells were incubated another 24 h before determination of cell viability.
Uptake of Ara-C and lysoPC Uptake of Ara-C was measured using 3 H-labeled Ara-C in the presence and absence of lysophosphatidylcholine. In short, cells were seeded in culture medium (10 6 cells/ml) and preincubated with or without lysoPC for 2 h. Then, 10 Ci Ara-C (20 Ci/mmol) was added together with unlabeled Ara-C to a concentration of 50 M. 14 C lysoPC (10 g/ml, 0.5 Ci) uptake was measured under the same conditions with a preincubation of the cells with 50 M Ara-C for 4 h. After indicated time intervals 2 ml aliquots of the cell suspension were taken and diluted 10-fold in ice-cold medium. The cells were centrifuged and the pellet was washed three times with 5 ml medium. After washing the cells were taken up in 1 ml bidestilled water and two 400 l aliquots were used for radiolabel counting in a Packard-Canberra (Frankfurt, Germany) Tricarb 300 C scintillation counter.
Ara-C metabolites
The presence of Ara-C metabolites in the cells was determined at 5 h and 24 h after the addition of Ara-C, as described elsewhere. 27 Briefly, cells were washed twice in 0.9% NaCl and then lysed by 0.0025 PIC A and 0.2% acetonitrile solution pH 3.0. Samples were separated by HPLC on a C 18 reversed phase column by 0.1 M KH 2 PO 4 , 0.005 PIC A and 0.5% acetonitril at pH 2.7 as an eluent.
Statistical analysis
Data were analyzed with Student's t-test using the Graphpad Instat2 Program (Graphpad, San Diego, CA, USA).
Results

Characteristics of the cell lines HL 60 and Raji
For the comparative studies of Ara-C effects on cellular lipid metabolism we used two human cell lines, the myeloid leuke- Table 1 shows the general characteristics of both cell lines with special emphasis on the membrane lipid composition. The lower protein and total phosphorus content, and the higher lipid phosphorus content of HL 60 cells indicate that, in comparison to Raji, in this cell line the ratio between the membrane compartment and the cytosol is shifted more in favor of the cellular membranes. Within the membranes most of the major phospholipids are distributed equally in both cell lines except for a significantly higher phosphatidylcholine (16.5 vs 11.8 nmol per million cells) and a slightly higher sphingomyeline amount (5.7 vs 2.4 nmol per million cells) in Raji cells. The amounts of cholesterol and triglycerides, the major fractions of the neutral lipids, are very similar in both cell lines. Raji cells, however, seem to contain far less diglycerides than HL 60 cells.
Ara-C induced effects on cell viability and lipid composition
In a first set of experiments we investigated the influence of high doses of Ara-C on cell viability of HL 60 and Raji cells. Figure 1 shows the growth characteristics observed for both cell lines after treatment with 50 M Ara-C for 4 h. It has to be noted, that during the first 6-8 h of incubation both cell lines maintain a high viability. However, after this period cell lysis begins even in the absence of Ara-C. In HL 60 cells this effect is more pronounced than in Raji cells. The viability of HL 60 deteriorates quickly to about 50% after 24 h, whereas Raji cells keep a viability of over 80%. Dose-response assays confirmed the higher resistance of Raji cells with IC 50 /LC 50 values of 1.14/Ͼ10 M Ara-C after 48 h of incubation vs 0.17/0.45 M Ara-C in HL 60 cells.
Next we analyzed changes of membrane phospholipid and neutral lipid composition induced by Ara-C by thin-layer chromatography. An Ara-C concentration of 50 M was chosen because preliminary dose finding experiments showed no further effects on cellular lipids at 75 or 100 M. Alterations of cellular lipids occurred as soon as 8 h after start of 
Effects of lysoPC on Ara-C-mediated toxicity
To elucidate further the significance of the changes of the PC content of the cells by Ara-C, we enlarged the cellular PC pool artificially. For this purpose we loaded HL 60 cells with lysoPC, which readily incorporates into the membranes where it is quickly reacylated at the sn-2 position to form PC. By this procedure the membrane content of PC in HL 60 cells was conserved at almost normal level in spite of treatment with Ara-C (Figure 4) . Additionally there was also a slight increase in SM and LPC level, which, however was statistically not significant.
The viability of HL 60 cells could hereby be maintained at 77% for 24 h, and at 70% for 48 h when additional lysoPC was given into the culture medium at 24 h (Table 2 ). In Raji cells the viability of the cells after Ara-C treatment was not influenced by lysoPC, probably because viability values were already high in the absence of lysoPC (see Figure 1) .
In order to evaluate the general validity of lysoPC protection of cells against Ara-C-induced cell toxicity, a panel of four different leukemic cell lines was tested: the human histiocytic cell line U 937, and the T cell lines Jurkat, TIB and HUT 78 ( Table 2 ). All cells showed variable but statistically significant protection against Ara-C toxicity by lysoPC, indicating that Ara-C-induced inhibition of PC synthesis may be a general phenomenon participating in varying degrees in Ara-C toxicity.
This conclusion could be further strengthened by investigations with primary blasts from patients with acute myeloid leukemia (Table 3 ). Leukemic cells from bone marrow aspirates were treated with lysoPC, Ara-C and a combination of both substances for 24 h. Apparently lysoPC alone had no effect on cell viability, but was able to reduce significantly Ara-C-induced loss of viability in four out of five patients tested. In patient 2 Ara-C reduced viability by 5% of control, which was statistically not significant. LysoPC did not improve viability. The characteristics of these blasts very much resembled those of Raji cells.
Figure 3
Uptake of Ara-C and lysoPC in HL 60 cells. Cells were incubated with 50 M 3 H Ara-C (10 Ci/mol) for indicated times in the presence () or absence (í) of 10 g/ml lysoPC (top) or they were incubated with 10 g/ml 14 C lysoPC (27.7 Ci/mol) in the presence (ć) or absence (b) of 50 M Ara-C (bottom). The cells were washed in ice-cold medium and cell-associated radioactivity was counted in a liquid scintillation counter. Data are mean values of three independent duplicate experiments.
Effects of lysoPC on Ara-C uptake and metabolism
As it was possible that the alterations of cellular resistance were mediated by mutual interference of Ara-C and lysoPC with their cellular incorporation, we performed uptake experiments with radiolabeled Ara-C and lysoPC in HL 60 cells ( Figure 3 ). As shown, nearly identical uptake curves were obtained for Ara-C and lysoPC in the cells in the presence and absence of either compound, indicating that lysoPC does not inhibit uptake of Ara-C and vice versa. The protection of cells by lysoPC must take place at a different level than uptake regulation of Ara-C.
Therefore, we investigated whether lysoPC had any influence on the metabolization of Ara-C in HL 60 cells by analysis of five different Ara-C metabolites during lysoPC treatment over a total time period of 24 h. An Ara-C concentration of 50 M and 5 h of incubation were previously chosen from dose-response determinations, because under these conditions metabolism mechanisms were saturated. After 5 h of exposition ( Figure 5a ) the cell line showed active metabolization of Ara-C, Ara-CTP being the most predominant metabolite, followed by Ara-CDP and Ara-CDP choline. After 24 h 
Table 3
Effects of lysoPC on Ara-C-induced toxicity in AML blasts Patient Control LysoPC Ara-C Ara-C + lysoPC of incubation with Ara-C, HL 60 cells showed a shift to Ara-U as the most abundant metabolite, followed by Ara-CTP and Ara-CDP choline. Raji cells incorporate far more Ara-C than HL 60 (Ara-CTP peak level of 535.2 ng/10 7 cells) while the distribution of metabolites resembles very much that of HL 60 cells (data not shown).
The metabolization seemed not to be influenced greatly by lysoPC after 5 h of incubation (Figure 5b) , with the exception of Ara-CDP choline, that was lower in cells in the presence of lysoPC by about 40% (25.2 vs 17 ng/10 7 cells). After 24 h lysoPC still had hardly any influence on the overall metabolism of Ara-C, but it produced a consistent decrease in Ara-CDP choline of 20%. Interestingly, the amount of original Ara-C was also reduced by lysoPC treatment by about 50%. Lyso-PC had no effect on Ara-C metabolization in Raji cells except a slight decrease of Ara-CDP choline (data not shown). 
Figure 5
Ara-C metabolism in the presence of lysoPC in HL 60 cells. HL 60 cells were incubated with 50 M Ara-C in the absence (a) or presence of 10 g/ml lysoPC (b). Incubations were stopped after 5 h (dotted panels) or 24 h (solid panels) and cells were processed for HPLC determination of Ara-C metabolites. Data show mean values of three independent duplicate experiments with s.d.
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Synergistic antiproliferative effects between Ara-C and hexadecylphosphocholine
To prove further the significance of PC reduction for the antiproliferative effect of Ara-C in HL 60 and Raji cells, we employed a cytotoxic derivative of lyso-PC, hexadecylphosphocholine (HePC). HePC by itself interferes with cellular PC metabolism by inhibition of CTP:phosphocholine cytidylyltransferase 28 and enhancement of PC degradation via a transfer of a phosphocholine group on SM. 29 As summarized in Table 4 , after 48 h of culture the cells showed different susceptibility towards Ara-C and HePC, the Raji cell line being the more resistant towards both substances. A combination treatment lead to a significant additive cytotoxic effect in both cell lines.
Discussion
Clinical observations in patients with AML and in vitro experiments with leukemic cell cultures indicated that treatment with high concentrations of Ara-C may involve other mechanisms of cell destruction than interaction with DNA. Highdose Ara-C leads to rapid blast clearance in patients and cell lysis in culture within 24 h. The structural similarity between some Ara-C metabolites such as Ara-CTP and the naturally occurring CTP, a cofactor of phosphatidylcholine (PC) biosynthesis, suggested that the cell membrane itself may be the target of Ara-C-mediated toxicity. Daly et al 9 showed that exposition of MOLT-4 cells to Ara-C caused a reduction of the steady-state level of PC and phosphatidylethanolamine (PE) before cell lysis. Kucera and Capizzi 20 demonstrated that Ara-CTP inhibited in vitro the CTP:phosphocholine cytidylyltransferase, the rate limiting enzyme of PC synthesis via CDPcholine. Furthermore, they showed that Ara-CDP choline is a terminal product of Ara-C metabolism generated by a reversal of the function of the enzyme CDP-choline:1,2-diacylglycerol cholinephosphotransferase.
However, until now, the significance of the postulated modulation of cellular PC metabolism by high-dose Ara-C treatment in leukemic cells with regard to Ara-C toxicity has not been evaluated. Thus, we decided to investigate the effects of Ara-C on cellular membrane lipids in the two cell lines Raji and HL 60, especially focusing on alterations of PC. Cell proliferation assays showed that Ara-C at high concentrations of 50 M induced cell lysis after 6-8 h of incubation. This effect was far more pronounced in HL 60 than in Raji cells, Table 4 Synergistic effects between Ara-C and HePC which generally appeared to be more resistant towards Ara-C. In the same time period, first alterations of membrane lipid distribution became detectable, reaching a plateau at 24 h of exposure to Ara-C. In HL 60 cells there was a decrease of PC content of about 20%, accompanied by an increase in triglycerides (TG) and diglycerides (DG). In contrast, Raji cells showed an increase in PC. Other membrane lipids remained unaffected.
Since both PC and TG synthesis use DG as a direct precursor, 21 it is likely that inhibition of PC synthesis in HL 60 cells has led to an enhanced acylation of DG to form TG. Strum et al 30 reported a similar but transient increase of DG and of ceramide within 30 min after Ara-C treatment in HL 60 cells. These authors conclude that the DG and ceramide peaks were generated from an activation of a neutral sphingomyelinase. This fast accumulation of second messenger molecules is typical for enzymes involved in signal transduction, whereas the slow increase of DG and TG observed in our experiments reflects a more general redirection of membrane lipid metabolism over a longer period of time. Changes of ceramide level were not detected at all, probably for the same reason. A possible explanation for the relative resistance of Raji cells towards Ara-C and the parallel increase of PC content may be that Raji cells escape Ara-C toxicity by maintaining high PC level through a shunt synthesis of PC over phosphatidylserine (PS) and PE, or they are protected from Ara-C simply because of their constitutively higher membrane PC content (16.5 vs 11.8 nmol/million cells in HL 60), regardless of any further increase of PC.
If membrane PC content determines the susceptibility of a cell to Ara-C-induced lysis at high doses, then an increase of PC should render the cells resistant towards this effect, on the other hand a further decrease of PC should intensify Ara-Cmediated toxicity. To test this assumption, HL 60 cells were incubated with 50 M Ara-C for 4 h followed by an incubation in the presence of 10 g/ml lysoPC. LysoPC is readily incorporated in the cellular membranes and rapidly acylated to PC. 29, 31 The increase of the membrane concentration of PC correlated well with a substantial protection of the cells from Ara-C-induced cell death. Similar experiments with other myeloid and lymphatic cell lines and primary AML blasts from patients proved that the antagonism of Ara-C toxicity by lysoPC seemed to be a general phenomenon. Apparently, lysoPC was metabolized rapidly, since the protection lasted only 24 h and another addition of lysoPC was necessary to maintain a relatively high viability until 48 h after treatment. Although lyso-phosphatidic acid (lysoPA) can act as a growth stimulus in fibroblasts, 32 lysoPC by itself showed no effects on cell proliferation nor did it influence Ara-C incorporation into the cells. The cell-protective effects of lysoPC were restricted to Ara-C, since doxorubicin-mediated toxicity could not be diminished (data not shown), arguing strongly in favor of very specific antagonistic relations between Ara-C and lysoPC. Further evidence for the above stated hypothesis was provided in experiments, when PC synthesis in HL 60 cells was inhibited additionally by hexadecylphosphocholine (HePC). HePC is an etherlipid analogue of lysoPC with antiproliferative activity against neoplastic cells. 33 One of the pleiotropic effects of this compound is the reduction of PC content by inhibition of the CTP:phosphocholine cytidylyltransferase, 28 the same enzyme that also seems to be inhibited by Ara-CTP, 20 and by enhanced transfer of a phosphocholine group from PC to sphingomyeline. 29 Combination treatment of Ara-C and HePC showed pronounced synergistic cytotoxic effects in HL 60 and Raji cells. It has to be stressed, however, that Raji cells tolerated far higher doses of both compounds, indicating that to bypass a decrease of membrane PC, maybe by alternative PC synthesis pathways over the above mentioned PS-shunt, could be a possible common mechanism of resistance towards Ara-C and HePC.
The antagonistic activity of lysoPC towards Ara-C prompted us to investigate whether this lysoPC effect may be mediated by alterations of Ara-C metabolism. The determinations of intracellular Ara-C metabolites after 5 h showed that Ara-CTP is the most abundant substance, followed by Ara-CDP-choline and Ara-CDP shifting to Ara-U as the predominant metabolite, followed by Ara-CTP and Ara-CDP-choline after 24 h of incubation. These results are consistent with previous reports from ourselves and other authors. [34] [35] [36] [37] [38] [39] [40] [41] [42] LysoPC did not significantly affect Ara-C metabolization, above all, it did not influence Ara-CTP, which has been considered the main metabolite for the cytotoxic activity of Ara-C via DNA interaction. [1] [2] [3] [4] Only Ara-CDP choline levels were reduced by treatment with lysoPC. Ara-CDP-choline seems to be a terminal metabolite, like Ara-U. Both substances accumulate with time. As the generation of Ara-CDP-choline is supposed to result from a reverted reaction of CDP-choline:diacylglycerol cholinephosphotransferase employing PC and Ara-CMP as substrates, 20 one would rather expect an enhanced accumulation of this metabolite when PC levels were increased. Surprisingly, however, lysoPC reduces Ara-CDP-choline content. It may well be that high PC levels, introduced from an alternative source than CDP-choline, decrease the need for formation of CDPcholine. But, this would only lead to a concomitant reduction of Ara-CDP-choline if this metabolite was synthesized via phosphocholine and Ara-CTP, a reaction that, at least in vitro, does not seem very likely as shown by Kucera and Capizzi. 20 On the other hand, lysoPC may directly inhibit the reversed reaction of CDP-choline:diacylglycerol cholinephosphotransferase, thereby reducing the generation of Ara-CDPcholine.
Interestingly, lysoPC also reduces the concentration of Ara-C after 24 h. As obviously a fixed amount of Ara-C is deaminated to Ara-U and lysoPC leads to a reduction of Ara-CDPcholine, there may be a higher demand for Ara-CDP-choline synthesis during which Ara-C is possibly consumed. Generally, it appears that these alterations of Ara-C metabolism do not offer a good explanation as to the mechanism of the cell protective effects of lysoPC from high-dose Ara-C treatment. Especially, the level of Ara-CTP which has been related to Ara-C cytotoxicity was not changed by lyso-PC in either cell line. Furthermore, Raji cells which were more resistant to Ara-C show higher Ara-CTP contents by far than the sensitive HL 60 cells.
In this paper we presented evidence that the postulated alternative mechanism of rapid cell destruction by high-dose Ara-C is significantly correlated with the PC content of the cell membrane. Although rapid cell disruption is usually seen when the membrane concentration of lysophospholipid structures exceeds 10 mol% of total phospholipids, which has not been observed here in Ara-C-mediated changes of membrane lipid composition, there are reports showing that changes of PC can also destabilize membranes in a short period of time. [43] [44] [45] Other potential mechanisms which have been discussed recently, such as interaction with intracellular signalling and induction of apoptosis 12, 14, 15, 17 do not sufficiently explain the fast cell death produced by high concentrations of Ara-C because they first, function on a larger time scale and second, Raji cells, expressing lower Bcl-2 levels than HL60 or Jurkat cells 46, 47 should then be more susceptible to Ara-Cinduced cell death by apoptosis. It is conceivable that these findings may have important clinical implications in the future. By use of appropriate membrane active substances, it may be possible to either potentiate Ara-C toxicity on neoplastic cells or to minimize undesired side-effects on normal tissues during high-dose Ara-C therapy.
